glp-1 cardiovascular outcome trials and heart health: what the largest trial in non-diabetics actually found. The SELECT trial tested semaglutide in 17,600+ people who had established cardiovascular disease and obesity but no diabetes — GLP-1 receptor agonists and cardiovascular

The bacteria L

Neurological symptoms (symptoms of problems in brain, spinal cord, or other nerves) Your hands and feet feel like they're numb or tingling

In DHEA-induced PCOS mice, oocytes show morphological abnormalities, reduced polar body extrusion, and excessive cytoplasmic ROS

This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption

Topical